A feedback loop between androgen receptor and erk signaling in estrogen receptor-negative breast cancer

Neoplasia

Volumn 13, Issue 2, 2011, Pages 154-166

  Chia, Kee Ming ^a   Liu, Ji ^a   Francis, Glenn D ^b   Naderi, Ali ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOTRANSFERASE; PROTEIN C FOS; S6 KINASE; TRANSCRIPTION FACTOR ELK 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOCRINE GLAND; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MOUSE; NONHUMAN; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

EID: 79951487669     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.101324     Document Type: Article

References (37)

1. Putti TC, El-Rehim DM, Rakha EA, Paish CE, Lee AH, Pinder SE, and Ellis IO (2005). Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis. Mod Pathol 18, 26-35.
2. Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, Fumoleau P, Larsimont D, Macgrogan G, Bergh J, Cameron D, Goldstein D, et al. (2005). Identificationof molecular apocrine breast tumours by microarray analysis. Oncogene 24, 4660-4671.
3. Teschendorff AE, Naderi A, Barbosa-Morais NL, and Caldas C (2006). PACK:Profile Analysis using Clustering and Kurtosis to find molecular classifiers incancer. Bioinformatics 15, 2269-2275.
4. Doane AS, Danso M, Lal P, Donaton M, Zhang L, Hudis C, and Gerald WL (2006). An estrogen receptor-negative breast cancer subset characterized by ahormonally regulated transcriptional program and response to and rogen. Oncogene 25, 3994-4008.
5. Naderi A and Hughes-Davies L (2008). A functionally significant cross-talkbetween androgen receptor and ErbB2 pathways in estrogen receptor negativebreast cancer. Neoplasia 10, 542-548.
6. Niemeier LA, Dabbas DJ, Beriwal S, Striebel JM, and Bhargava R (2009). Androgenreceptor in breast cancer: expression in estrogen receptor-positive tumorsand in estrogen receptor-negative tumors with apocrine differentiation. Mod Pathol 23, 205-212.
7. Park S, Koo J, Park HS, Kim JH, Choi SY, Lee JH, Park BW, and Lee KS (2009). Expression of androgen receptors in primary breast cancer. Ann Oncol 21, 488-492.
8. Vranic S, Tawfik O, Palazzo J, Bilalovic N, Eyzaguirre E, Lee LMJ, Adegboyega P, Hagenkord J, and Gatalica Z (2010). EGFR and HER-2/neu expression in invasiveapocrine carcinoma of the breast. Mod Pathol 23, 644-653.
9. Banneau G, Guedj M, Macgrogan G, de Mascarel L, Velasco V, Schiappa R, Bonadona V, David A, Dugast C, Gilbert-Dussardier B, et al. (2010). Molecularapocrine differentiation is a common feature of breast cancer in patients withgermline PTEN mutations. Breast Cancer Res 12, R63.
10. Naderi A and Liu J (2010). Inhibition of androgen receptor and Cdc25A phosphataseas a combination targeted therapy in molecular apocrine breast cancer. Cancer Lett 298, 74-87.
11. Sanga S, Broom BM, Cristini V, and Edgerton ME (2009). Gene expressionmeta-analysis supports existence of molecular apocrine breast cancer with a rolefor androgen receptor and implies interactions with ErbB family. BMC Med Genomics 2, 59.
12. Frodin M and Gammeltoft S (1999). Role and regulation of 90 kDa ribosomal S6 kinase (RSK) in signal transduction. Mol Cell Endorcinol 151, 65-77.
13. Cruzalegui FH, Cano E, and Treisman R (1999). ERK activation induces phosphorylationof Elk-1 at multiple S/T-P motifs to high stoichiometry. Oncogene 18, 7948-7957.
14. Yarden Y and Sliwkowski MX (2001). Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2, 127-137.
15. Shigemura K, Isotani S, Wang R, Fujisawa M, Gotoh A, Marshall FF, Zhau HE, and Chung LW (2009). Soluble factors derived from stroma activated androgenreceptor phosphorylation in human prostate LNCaP cells: roles of ERK/MAPkinase. Prostate 69, 949-955.
16. Leotoing L, Manin M, Monte D, Baron S, Communal Y, Lours C, Veyssiere G, Morel L, and Beaudoin C (2007). Crosstalk between androgen receptor andepidermal growth factor receptor-signalling pathways: a molecular switch forepithelial cell differentiation. J Mol Endocrinol 39, 151-162.
17. Naderi A, Liu J, and Bennett IC (2010). BEX2 regulates mitochondrial apoptosisand G1 cell cycle in breast cancer. Int J Cancer 126, 1596-1610.
18. Naderi A, Teschendorff AE, Beigel M, Cariati M, Ellis IO, Brenton JD, and Caldas C (2007). BEX2 is overexpressed in a subset of primary breast cancersand mediates nerve growth factor/nuclear factor-kappa B inhibition of apoptosisin breast cancer cell lines. Cancer Res 67, 6725-6736.
19. Naderi A, Liu J, and Hughes-Davies L (2010). BEX2 has a functional interplaywith c-Jun/JNK and p65/Rel A in breast cancer. Mol Cancer 19, 111.
20. Cariati M, Naderi A, Brown JP, Smalley MJ, Pinder SE, Caldas C, and Purushotham AD (2008). α6 Integrin is necessary for the tumourigenicity of astem cell-like sub-population within the MCF7 breast cancer cell line. Int JCancer 122, 298-304.
21. Hoeflich KP, O'Brien C, Boyd Z, Cavet G, Guerrero S, Jung K, Januario T, Savage H, Punnoose E, Truong T, et al. (2009). In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancermodels. Clin Cancer Res 15, 4649-4664.
22. Bourguignon LY, Gilad E, and Peyrollier K (2007). Heregulin-mediated ErbB2-ERK signaling activates hyaluronan synthases leading to CD44-dependent ovariantumor cell growth and migration. J Biol Chem 282, 19426-19441.
23. Lonze BE and Ginty DD (2002). Function and regulation of CREB family transcriptionfactors in the nervous system. Neuron 35, 605-623.
24. Xing J, Ginty D, and Greenberg ME (1996). Coupling of the RAS-MAPK pathwayto gene activation by RSK2, a growth factor-regulated CREB kinase. Science 273, 959-963.
25. De Cesare D, Jacquot S, Hanauer A, and Sassone-Corsi P (1998). Rsk-2 activity isnecessary for epidermal growth factor-induced phosphorylation of CREB proteinand transcription of c-fos gene. Proc Natl Acad Sci USA 95, 12202-12207.
26. Yang SH, Yates PR, Whitmarsh AJ, Davis RJ, and Sharrocks AD (1998). The Elk-1 ETS-domain transcription factor contains a mitogen-activated protein kinasetargeting motif. Mol Cell Biol 18, 710-720.
27. Wang Y and Prywes R (2000). Activation of the c-fos enhancer by the Erk MAPkinase pathway through two sequence elements: the c-fos AP-1 and p62TCF sites. Oncogene 19, 1379-1385.
28. Peterziel H, Mink S, Schonert A, Becker M, Klocker H, and Cato AC (1999). Rapidsignalling by androgen receptor in prostate cancer cells. Oncogene 18, 6322-6329.
29. Unni E, Sun S, Nan B, McPhaul MJ, Cheskis B, Mancini MA, and Marcelli M (2004). Changes in androgen receptor nongenotropic signaling correlate with transitionof LNCaP cells to androgen independence. Cancer Res 64, 7156-7168.
30. Diaz LK and Sneige N (2005). Estrogen receptor analysis for breast cancer: currentissues and keys to increasing testing accuracy. Adv Anat Pathol 12, 101-109.
31. Harvey LM, Clark GM, Osborne CK, and Allred DC (1999). Estrogen receptorstatus by immunohistochemistry is superior to the ligand-binding assay for predictingresponse to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17, 1474-1481.
32. Yeh S, Lin HK, Kang HY, Thin TH, Lin MF, and Chang C (1999). From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway byinduction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci USA 96, 5458-5463.
33. Craft N, Shostak Y, Carey M, and Sawyers CL (1999). A mechanism for hormoneindependentprostate cancer through modulation of androgen receptor signalingby the HER-2/neu tyrosine kinase. Nat Med 5, 280-285.
34. Carey AM, Pramanik R, Nicholson LJ, Dew TK, Martin FL, Muir GH, and Morris JDH (2007). Ras-MEK-ERK signaling cascade regulates androgen receptorelement-inducible gene transcription and DNA synthesis in prostate cancer cells. Int J Cancer 121, 520-527.
35. Xing J, Kornhauser JM, Xia Z, Thiele EA, and Greenberg ME (1998). Nervegrowth factor activates extracellular signal-regulated kinase and p38 mitogenactivatedprotein kinase pathways to stimulate CREB serine 133 phosphorylation. Mol Biol Cell 18, 1946-1955.
36. Wiggin GR, Soloaga A, Foster JM, Murray-Tait V, Cohen P, and Arthur JS (2002). MSK1 and MSK2 are required for the mitogen- and stress-induced phosphorylationof CREB and ATF1 in fibroblasts. Mol Biol Cell 22, 2871-2881.
37. Mayr B and Montminy M (2001). Transcriptional regulation by the phosphorylationdependentfactor CREB. Nat Rev Mol Cell Biol 2, 599-609.